Year: 2020

news_6

Exelixis Announces Takeda and Ono Submit Supplemental Application for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable, Advanced or Metastatic Renal Cell Carcinoma in Japan

news_6

EdiGene Announces IND Application for its CRISPR/Cas 9 Gene-editing Hematopoietic Stem Cell Therapy ET-01 in ?-thalassemia Accepted for Review by China National Medical Products Administration

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--EdiGene, Inc. ( “Company”, or “EdiGene”), today announced the Center for Drug Evaluation (CDE) of China...